| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 2, 2007
Accepted on March 6, 2007
Fertility Preservation Program, Center for Reproductive Medicine & Infertility, Weill Medical College of Cornell University, New York, New York
* To whom correspondence should be addressed. E-mail: kuo9001{at}med.cornell.edu.
Context: Breast cancer patients undergoing controlled ovarian hyperstimulation (COH) for embryo or oocyte cryopreservation should be induced by the method that leads to least increase in estradiol levels.
Objective: To determine the potency of anastrozole to suppress serum estradiol levels in breast cancer patients undergoing COH.
Design: Prospective sequential cohort study between May 2003 and November 2005 for letrozole, and December 2005 and April 2006 for anastrozole.
Setting: Academic center for reproductive medicine.
Patients: Breast cancer patients presenting for fertility preservation
Intervention: COH using FSH and letrozole (n=47) or anastrozole (n=7), followed by oocyte retrieval and embryo cryopreservation.
Main outcome measures: Serum estradiol levels, area under the curve (AUC) for estradiol, and outcomes of COH cycles.
Results: There were no significant differences between the two groups regarding length of stimulation, total gonadotropin dose, number of follicles >17mm and the lead follicle size on hCG day and number of embryos cryopreserved. The mean E2 on the day of hCG and post-hCG days were higher in the anastrozole group compared to the letrozole group (1325.89±833.17 and 2515.07±1368.52 vs. 427.78±278.24 and 714.38±440.83 pg.d/mL, p 
0.01), respectively, even when anastrozole dose was increased up to 10mg per day. The mean AUC was significantly higher in the anastrozole group compared to the letrozole group (4402.93 ± 1526.7 pg.d/mL vs. 1287.48 ± 732.17 pg.d/mL, p <0.004).
Conclusions: Breast cancer patients who underwent ovarian stimulation with anastrozole had a significantly higher exposure to estradiol than those who were stimulated with letrozole.
This article has been cited by other articles:
 |
|
 |
|
  T. Tulandi, J. Y. J. Huang, and S. L. Tan Preservation of Female Fertility: An Essential Progress Obstet. Gynecol., November 1, 2008; 112(5): 1160 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mieszczak, E. S. Lowe, P. Plourde, and E. A. Eugster The Aromatase Inhibitor Anastrozole Is Ineffective in the Treatment of Precocious Puberty in Girls with McCune-Albright Syndrome J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2751 - 2754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Azim, M. Costantini-Ferrando, and K. Oktay Safety of Fertility Preservation by Ovarian Stimulation With Letrozole and Gonadotropins in Patients With Breast Cancer: A Prospective Controlled Study J. Clin. Oncol., June 1, 2008; 26(16): 2630 - 2635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R. Schover Premature Ovarian Failure and Its Consequences: Vasomotor Symptoms, Sexuality, and Fertility J. Clin. Oncol., February 10, 2008; 26(5): 753 - 758. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
